查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1339169

子宮肌瘤治療市場、份額、規模、趨勢、行業分析報告:按藥物類別、按藥物類型、按最終用途、按地區、按細分市場、預測，2023-2032 年

Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, & Segment Forecasts, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，到2032年，全球子宮肌瘤治療市場規模預計將達到108.3億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

子宮肌瘤（UF）是影響育齡婦女的常見疾病，經血過多是最常見的症狀之一。 GnRH 拮抗劑和釋放孕激素的子宮內避孕器等新型藥物的開發為患有子宮肌瘤的女性提供了更有效的治療選擇。 這些因素，加上意識和診斷的提高，正在推動市場成長。

根據 IntechOpen 的分析，月經過多是 UF 最常見的症狀，每年影響近 140 萬名女性。 此外，約 60% 的女性報告有體力活動減少和生活品質下降等症狀。

對更有效、更安全的子宮肌瘤治療方法的需求不斷增加，這是該領域研究和開發的驅動力。 隨著研究活動資金的增加，更先進和創新療法的開發預計將進一步推動市場成長。 此外，個人化醫療和精準治療的發展也有望推動市場成長，因為它有可能為個別患者提供更有針對性和更有效的治療選擇。

最近，婦女健康研究協會(SWHR) 批准並重新提出了《2021 年斯蒂芬妮.塔布斯.瓊斯子宮肌瘤研究和教育法案》。希望這將資助和支持肌瘤研究並加速新療法的開發。 此外，最近批准了幾種 GnRH 拮抗劑（包括 myfenbrey）用於治療與子宮肌瘤相關的嚴重出血，這可能會支持市場成長。

子宮肌瘤治療市場報告重點

GnRH 拮抗劑部分由於其高效和有效的治療選擇預計將增長更快。

黏膜下子宮肌瘤市場佔最大份額。 這主要是由於其高盛行率和嚴重性。 常見於亞洲女性

由於藥物和其他聯合療法易於取得，零售藥局市場預計將佔據很大份額

由於美國的高盛行率、醫療設施的可用性以及個人對其有害影響的高度認識，預計北美將出現更大的增長。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球子宮肌瘤治療市場洞察

  • 子宮肌瘤治療市場 - 最終用途概況
  • 子宮肌瘤治療市場動態
    • 推動者和機會
      • 子宮肌瘤患者的人增加
      • 努力提高人們對子宮肌瘤診斷和治療的認識
    • 抑制因素和挑戰
      • 嚴格的監理框架
  • PESTEL 分析
  • 子宮肌瘤治療市場最終用途趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章全球子宮肌瘤治療市場（依藥物類別）

  • 主要發現
  • 簡介
  • 促性腺激素釋放激素 (GnRH) 激動劑
  • 促性腺激素釋放激素 (GnRH) 拮抗劑
  • 釋放黃體素的子宮內避孕器 (IUD) 和避孕藥具
  • 非荷爾蒙藥物
  • 其他

第 6 章全球子宮肌瘤治療市場（依藥物類型）

  • 主要發現
  • 簡介
  • 漿膜下肌瘤
  • 壁內肌瘤
  • 黏膜下肌瘤
  • 帶蒂肌瘤

第 7 章全球子宮肌瘤治療市場，依最終用途劃分

  • 主要發現
  • 簡介
  • 醫院藥房
  • 零售藥局
  • 其他

第 8 章全球子宮肌瘤治療市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年子宮肌瘤治療市場評估（按地區）
  • 子宮肌瘤治療市場 - 北美
    • 北美:子宮肌瘤治療市場，依藥物類別，2019-2032 年
    • 北美:子宮肌瘤治療市場（以最終用途），2019-2032 年
    • 北美:子宮肌瘤治療市場（以藥物類型），2019-2032 年
    • 子宮肌瘤治療市場 - 美國
    • 子宮肌瘤治療市場 - 加拿大
  • 子宮肌瘤治療市場 - 歐洲
    • 歐洲:子宮肌瘤治療市場，依藥物類別，2019-2032 年
    • 歐洲:子宮肌瘤治療市場（以最終用途），2019-2032 年
    • 歐洲:子宮肌瘤治療市場，依藥物類型，2019-2032 年
    • 子宮肌瘤治療市場 - 英國
    • 子宮肌瘤治療市場 - 法國
    • 子宮肌瘤治療市場 - 德國
    • 子宮肌瘤治療市場 - 義大利
    • 子宮肌瘤治療市場 - 西班牙
    • 子宮肌瘤治療市場 - 荷蘭
    • 子宮肌瘤治療市場 - 俄羅斯
  • 子宮肌瘤治療市場 - 亞太地區
    • 亞太地區:子宮肌瘤治療市場，依藥物類別，2019-2032 年
    • 亞太地區:子宮肌瘤治療市場（依最終用途），2019-2032 年
    • 亞太地區:子宮肌瘤藥物市場（依藥物類型），2019-2032 年
    • 子宮肌瘤治療市場 - 中國
    • 子宮肌瘤治療市場 - 印度
    • 子宮肌瘤治療市場 - 馬來西亞
    • 子宮肌瘤治療市場 - 日本
    • 子宮肌瘤治療市場 - 印度尼西亞
    • 子宮肌瘤治療市場 - 韓國
  • 子宮肌瘤治療市場 - 中東和非洲
    • 中東和非洲:子宮肌瘤治療市場（按藥物類別），2019-2032 年
    • 中東和非洲:子宮肌瘤治療市場（以最終用途），2019-2032 年
    • 中東和非洲:子宮肌瘤治療市場（按藥物類型），2019-2032 年
    • 子宮肌瘤治療市場 - 沙烏地阿拉伯
    • 子宮肌瘤治療市場 - 阿聯酋
    • 子宮肌瘤治療市場 - 以色列
    • 子宮肌瘤治療市場 - 南非
  • 子宮肌瘤治療市場 - 拉丁美洲
    • 拉丁美洲:子宮肌瘤治療市場，依藥物類別，2019-2032 年
    • 拉丁美洲:子宮肌瘤治療市場（以最終用途），2019-2032 年
    • 拉丁美洲:子宮肌瘤治療市場，依藥物類型，2019-2032 年
    • 子宮肌瘤治療市場 - 墨西哥
    • 子宮肌瘤治療市場 - 巴西
    • 子宮肌瘤治療市場 - 阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • Myovant Sciences
  • Pfizer
  • Abbvie
  • Ferring
  • AstraZeneca
  • Bayer
  • Amring Pharmaceuticals
  • Watson Pharma
Product Code: PM3549

The global uterine fibroid treatment market size is expected to reach USD 10.83 billion by 2032, according to a new study by Polaris Market Research. The report "Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Uterine fibroids (UF) are a common condition affecting women of reproductive age, with heavy menstrual bleeding being one of the most common symptoms. The development of novel drugs, such as GnRH antagonists and progestin-releasing IUDs, has provided more effective treatment options for women with uterine fibroids. These factors, along with increased awareness and diagnosis, are driving the growth of the market.

As per the analysis done by the IntechOpen, excessive menstrual bleeding is the most common symptom in the UF, affecting almost 1.4 Mn women each year. Moreover, around 60 percent of the women have reported the symptoms of physical in-activity and quality of life.

Demand for more effective and safer treatment options for uterine fibroids is increasing, and this is driving research and development efforts in the field. With increased funding for research activities, the development of more advanced and innovative treatment options is expected, which will further drive the growth of the market. Additionally, the development of personalized medicine and precision therapies is also expected to drive growth in the market, as these approaches may offer more targeted and effective treatment options for individual patients.

The recent endorsement and reintroduction of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 by the Society for Women's Health Research (SWHR) will provide funding and support for research on uterine fibroids, which is expected to boost the development of novel treatments. Additionally, the recent approval of multiple GnRH antagonists such as Myfembree for the treatment of heavy bleeding associated with fibroids will also drive the market growth.

Uterine Fibroids Treatment Market Report Highlights

GnRH antagonists' segment is anticipated to witness faster growth owing to its high efficacy and effective treatment option.

Sub-mucosal fibroids segment accounted for the larger market share. This is primarily due its high prevalence rate and severity. It is most common among Asian women

Retail pharmacies segment expected to garner substantial share, owing to easy availability of drugs and other combination therapies

North America is expected to grow larger revenue, owing to high prevalence rate in the US. presence of better medical facilities, and awareness among individuals about ill effects.

The global players include: Myovant Sciences, Pfizer, Abbvie, Ferring, AstraZeneca, Bayer, Amring Pharmaceuticals, and Watson Pharma.

Polaris Market Research has segmented the uterine fibroids treatment market report based on drug type, drug class, end use, and region:

Uterine Fibroids Treatment, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroids Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Gonadotropin-releasing Hormone (GnRH) Agonists
  • Gonadotropin-releasing Hormone (GnRH) Antagonists
  • Progestin-releasing Intrauterine Device (IUD) & Contraceptives
  • Non-hormonal Medications
  • Others

Uterine Fibroids Treatment, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroids Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data End Uses
    • 3.2.1. Primary End Uses
    • 3.2.2. Secondary End Uses

4. Global Uterine Fibroid Treatment Market Insights

  • 4.1. Uterine Fibroid Treatment Market - End Use Snapshot
  • 4.2. Uterine Fibroid Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Population Base For Uterine Fibroids Patients
      • 4.2.1.2. Growing Awareness Initiatives Related To Uterine Fibroids Diagnosis And Treatment
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Stringent Regulatory Framework
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Uterine Fibroid Treatment Market End Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Uterine Fibroid Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. Gonadotropin-releasing Hormone (GnRH) Agonists
    • 5.3.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Agonists, by Region, 2019-2032 (USD Billion)
  • 5.4. Gonadotropin-releasing Hormone (GnRH) Antagonists
    • 5.4.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Antagonists, by Region, 2019-2032 (USD Billion)
  • 5.5. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
    • 5.5.1. Global Uterine Fibroid Treatment Market, by Progestin-releasing Intrauterine Device (IUD) & Contraceptives, by Region, 2019-2032 (USD Billion)
  • 5.6. Non-hormonal Medications
    • 5.6.1. Global Uterine Fibroid Treatment Market, by Non-hormonal Medications, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Uterine Fibroid Treatment Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Uterine Fibroid Treatment Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 6.3. Subserosal Fibroids
    • 6.3.1. Global Uterine Fibroid Treatment Market, by Subserosal Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.4. Intramural Fibroids
    • 6.4.1. Global Uterine Fibroid Treatment Market, by Intramural Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.5. Submucosal Fibroids
    • 6.5.1. Global Uterine Fibroid Treatment Market, by Submucosal Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.6. Pedunculated Fibroids
    • 6.6.1. Global Uterine Fibroid Treatment Market, by Pedunculated Fibroids, by Region, 2019-2032 (USD Billion)

7. Global Uterine Fibroid Treatment Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Uterine Fibroid Treatment Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Uterine Fibroid Treatment Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Uterine Fibroid Treatment Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Uterine Fibroid Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Uterine Fibroid Treatment Market - North America
    • 8.3.1. North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4. Uterine Fibroid Treatment Market - U.S.
      • 8.3.4.1. U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5. Uterine Fibroid Treatment Market - Canada
      • 8.3.5.1. Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4. Uterine Fibroid Treatment Market - Europe
    • 8.4.1. Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4. Uterine Fibroid Treatment Market - UK
      • 8.4.4.1. UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5. Uterine Fibroid Treatment Market - France
      • 8.4.5.1. France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6. Uterine Fibroid Treatment Market - Germany
      • 8.4.6.1. Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7. Uterine Fibroid Treatment Market - Italy
      • 8.4.7.1. Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8. Uterine Fibroid Treatment Market - Spain
      • 8.4.8.1. Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9. Uterine Fibroid Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10. Uterine Fibroid Treatment Market - Russia
      • 8.4.10.1. Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5. Uterine Fibroid Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4. Uterine Fibroid Treatment Market - China
      • 8.5.4.1. China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5. Uterine Fibroid Treatment Market - India
      • 8.5.5.1. India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6. Uterine Fibroid Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7. Uterine Fibroid Treatment Market - Japan
      • 8.5.7.1. Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8. Uterine Fibroid Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9. Uterine Fibroid Treatment Market - South Korea
      • 8.5.9.1. South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6. Uterine Fibroid Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4. Uterine Fibroid Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5. Uterine Fibroid Treatment Market - UAE
      • 8.6.5.1. UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6. Uterine Fibroid Treatment Market - Israel
      • 8.6.6.1. Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7. Uterine Fibroid Treatment Market - South Africa
      • 8.6.7.1. South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7. Uterine Fibroid Treatment Market - Latin America
    • 8.7.1. Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4. Uterine Fibroid Treatment Market - Mexico
      • 8.7.4.1. Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5. Uterine Fibroid Treatment Market - Brazil
      • 8.7.5.1. Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6. Uterine Fibroid Treatment Market - Argentina
      • 8.7.6.1. Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Myovant Sciences
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Drug Class Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Drug Class Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Abbvie
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Drug Class Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Ferring
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Drug Class Benchmarking
    • 10.4.4. Recent Development
  • 10.5. AstraZeneca
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Drug Class Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Bayer
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Drug Class Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Amring Pharmaceuticals
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Drug Class Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Watson Pharma
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Drug Class Benchmarking
    • 10.8.4. Recent Development

List of Tables

  • Table 1 Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 3 Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 4 Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 7 North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 19 UK: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 20 France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 22 France: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 43 China: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 44 India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 46 India: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Uterine Fibroid Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Type
  • Figure 7. Global Uterine Fibroid Treatment Market, by Drug Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Uterine Fibroid Treatment Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Uterine Fibroid Treatment Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 12. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Uterine Fibroid Treatment Market